- Home
- FER vs ONC Comparison
FER vs ONC Comparison
Compare FER & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FER
- ONC
- Stock Information
- Founded
- FER 1952
- ONC 2010
- Country
- FER Netherlands
- ONC Cayman Islands
- Employees
- FER N/A
- ONC N/A
- Industry
- FER
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- FER
- ONC Health Care
- Exchange
- FER NYSE
- ONC Nasdaq
- Market Cap
- FER 33.1B
- ONC 26.9B
- IPO Year
- FER N/A
- ONC N/A
- Fundamental
- Price
- FER $49.31
- ONC $235.17
- Analyst Decision
- FER
- ONC Strong Buy
- Analyst Count
- FER 0
- ONC 7
- Target Price
- FER N/A
- ONC $326.43
- AVG Volume (30 Days)
- FER 127.6K
- ONC 502.3K
- Earning Date
- FER 01-01-0001
- ONC 05-07-2025
- Dividend Yield
- FER 1.68%
- ONC N/A
- EPS Growth
- FER 618.58
- ONC N/A
- EPS
- FER 4.63
- ONC N/A
- Revenue
- FER $9,469,924,426.00
- ONC $4,175,868,000.00
- Revenue This Year
- FER $4.97
- ONC $860.73
- Revenue Next Year
- FER $3.71
- ONC $19.79
- P/E Ratio
- FER $10.57
- ONC N/A
- Revenue Growth
- FER 7.43
- ONC 51.16
- 52 Week Low
- FER $37.00
- ONC $141.31
- 52 Week High
- FER $56.43
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- FER N/A
- ONC N/A
- Support Level
- FER N/A
- ONC N/A
- Resistance Level
- FER N/A
- ONC N/A
- Average True Range (ATR)
- FER 0.00
- ONC 0.00
- MACD
- FER 0.00
- ONC 0.00
- Stochastic Oscillator
- FER 0.00
- ONC 0.00
About FER FERROVIAL SE
Ferrovial SE is a Spanish industrial company. The company organizes itself into four segments: Toll Roads, Airports, Construction, and Energy. The Toll Roads segment develops and operates toll roads globally. The Airports segment includes the Development, financing and operation of airports. The Construction segment Designs and executes all public and private works, including most notably the construction of public infrastructures. The Energy segment focuses on innovative solutions for promoting, constructing and operating energy generation and transmission infrastructures.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.